Injection Resources

Injection Resources

Janssen CarePath provides injection support resources that may assist you and your patients.

TREMFYA® Injection Training Support Program

The TREMFYA® Injection Training Support Program provides patients with additional training support to continue their TREMFYA® treatment with confidence.

How the Program works:

  1. The self-injection training is conducted live by a Registered Nurse, either in-person or over the phone*
  2. Your patient can only enroll once you, their healthcare provider, and your patient have confirmed that initial self-injection training has been completed in your office
  3. This program is intended as patient education to reinforce proper injection technique

To have your patients enroll in the TREMFYA® Injection Training Support Program, they must first fill out a program enrollment form, which you can provide after they have met the program eligibility requirements.


The TREMFYA® Injection Training Support Program is limited to education for patients about their Janssen therapy, its administration, and/or their disease. It is intended to supplement a patient's understanding of their therapy, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, provide case management services, or serve as a reason to prescribe.

*In-person live training may not be available in all areas.

A Nurse is Just a Phone Call Away
Even after you’ve trained your patients to give themselves an injection of TREMFYA®, they may still have questions. Janssen Nurse Support* can help answer their questions about giving themselves an injection at home, preparing their injection site prior to self-injecting, and properly disposing of their used syringe.

Connect your patients with Janssen Nurse Support at 877-CarePath (877-227-3728), available Monday – Friday, 9:00 AM – 8:00 PM ET. At all other times, a nurse will typically return their call in 15 minutes.

*The nurse program is limited to education for patients about their Janssen therapy, its administration, and/or their disease, and is not intended to provide medical advice, replace a treatment plan from the patient's doctor or nurse, or provide case management services.


TREMFYA® is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

TREMFYA® is administered as a 100 mg subcutaneous injection once every 8 weeks, after starter doses at weeks 0 and 4. TREMFYA® is intended for use under the guidance and supervision of a physician. Patients may self-inject with TREMFYA® after physician approval and proper training.


Important Safety Information For TREMFYA®

Important Safety Information

TREMFYA® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.

TREMFYA® may increase the risk of infection. Treatment with TREMFYA® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.

Consider the risks and benefits of treatment prior to prescribing TREMFYA® in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving TREMFYA® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA® until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis (TB)
Evaluate patients for TB infection prior to initiating treatment with TREMFYA®. Initiate treatment of latent TB prior to administering TREMFYA®. Monitor patients for signs and symptoms of active TB during and after TREMFYA® treatment. Do not administer TREMFYA® to patients with active TB infection.

Hypersensitivity Reactions
Serious hypersensitivity reactions have been reported with postmarket use of TREMFYA®, some cases required hospitalization. If a serious hypersensitivity reaction occurs, discontinue TREMFYA® and initiate appropriate therapy.

Prior to initiating TREMFYA®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TREMFYA®.

Most common (≥1%) adverse reactions associated with TREMFYA® include upper respiratory infections, headache, injection site reactions, arthralgia, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections.

Please read the full Prescribing Information and Medication Guide for TREMFYA®. Provide the Medication Guide to your patients and encourage discussion.